It should be noted that dysregulation of AMPK signaling is prevalent in AD, suggesting that further manipulation of this pathway may, at best, fail to achieve the observed benefits when used in combination of existing AD-associated pathologies and at worst, exacerbate AD-associated symptoms. Here, PRKAA2 is linked to Alzheimer disease.